Focus and Scope

Since 2005 the “Clinical and experimental thyroidology” (or «Klinicheskaia i eksperimentalnaia tiroidologia”) Journal publishes timely articles, balancing both clinical and experimental research, case reports, reviews and lectures on pressing problems of thyroid pathology.

The Journal:

  • features original national and foreign research articles, reflecting world thyroidology development
  • publishes chronicle of major international congress sessions and workshops on thyroidologe;
  • is intended for scientists, diabetologists, endocrinologists and specialists of allied trade, general practitioners, family physicians and pediatricians.

 

Section Policies

Review of literature

The journal publishes reviews of literature, including systematic reviews of clinical trials in different directions of thyroidology and related areas.

The main purpose of writing should be a discussion of the accumulated data and presentation of the new authorial view of the previously proven facts, rethinking and new approaches to their handling, but not a simple enumeration and a statement of the present condition of the question. Thus, the discussion is a mandatory part of the review (it can be isolated in a separate section or place systematically throughout the text).

There must be presented all the sources of primary information (full-text and abstract databases) in the manuscript. Also the author should describe in detail the procedure of information search: names of databases, filters and keywords, as well as any additional conditions of selection of primary sources.

The manuscript of literature review should be structured into sections and contain graphic materials.

Checked Open Submissions Checked Indexed Checked Peer Reviewed

Original Studies

The journal publishes the results of international and local clinical and experimental studies, and meta-analyzes   in the area of thyroidology and related specialties.

The journal publishes the results of research involving human subjects, as well as experimental studies in vitro and animal studies. Journal does not publish experimental and clinical studies of dietary supplements.

Clinical and experimental studies, which are described in the manuscript, must be conducted in accordance with internationally accepted principles of ethics and deontology. Editorial staff asks the authors to describe the facts that the study was conducted  in accordance with  international standards GCP (voluntary signing of the informed consent of all participants in the study, examination of the study protocol by the ethics committee with the distinct name of ethics committee, the meeting date and protocol number, etc.).

There must be presented detailed study protocol in the part of manuscript named describing of the work. The authir should give as many details so that the study protocol can be fully played. In the case of meta-analyze the author should describe in detail the procedure of information search: names of databases, filters and keywords, as well as any additional conditions of selection of primary sources.

In compliance with the ethics editorial staff asks authors to indicate the source of funding of the work (study, writing and publishing articles, etc.), and declare the presence or absence of apparent or potential conflicts of interest.  Please note that the presence of obvious or potential conflict of interest (including the financial interest of the authors) or affiliation of any organization (public or private) with conduction of the research is not a reason for refusing to publish the manuscript. Rather, this information talks about the openness of the authors and reliability of results. It gives additional advantages of manuscript under evaluation by reviewers and will cause more interest and trust of readers.

Checked Open Submissions Checked Indexed Checked Peer Reviewed

Case Report

The journal publishes case reports in the area of thyroidology and related specialties.

Potential topics for case reports are

  • diagnosis: new or rare diseases or unusual presentation of common diseases, uncertain diagnosis, unusual presentation of more common disease, discussion of differential diagnoses, novel diagnostic procedures;
  • treatment: new treatments or established treatments in new situations, treatment of rare diseases, unique technical procedures, unexpected outcomes or effects, adverse events or unanticipated events;
  • special circumstances: highly individualized treatments, complex situations, integration of multiple therapies, ethical challenges, learning from errors, findings that shed new light on the possible pathogenesis of a disease or an adverse effect.

The main purpose of writing should be presentation of information on clinical cases that present a diagnostic, ethical or management challenge, or that highlight aspects of mechanisms of injury, pharmacology or histopathology and discussion of the accumulated facts, comparison between current information and previously proven data.

We recommend all authors to hold to manuscript structure and chronologize the facts.

Report common information about the patient’s disease. In case your case reports is devoted to treatment challenge, describe the medication, its indications and usage and potential side effects. A summary of data on the topic may be also presented.

Briefly summarize the background of this case report. Describe the patient characteristics (such as the relevant demographics—age, gender, ethnicity, occupation) and their presenting concerns with relevant details of related past interventions. Also, present the medical, family, and psychosocial history including lifestyle and genetic information, other pertinent co-morbidities and interventions (other therapies including self-care).

Presentation of this case should include the following:

  • symptoms of the disorder,
  • physical examination focused on the important findings including results from testing,
  • diagnostic methods (including laboratory testing, imaging results, questionnaires, referral diagnostic information),
  • diagnostic challenges (such as limited ability to complete an evaluation, patient availability, cultural) and diagnostic reasoning including other diagnoses considered,
  • interventions (such as pharmacologic, surgical, preventive, lifestyle, self-care)
  • administration and intensity of the intervention (including dosage, strength, duration, frequency),
  • prognostic characteristics.

Please describe the strengths and limitations of this case report including case management, and the scientific and medical literature related to this case report. Discuss the rationale for your conclusions such as potential causation and the ways this case might be generalized to a larger population. Finally, what are the main findings of this case report and what are the 'take-away' messages?

 

Checked Open Submissions Checked Indexed Checked Peer Reviewed

Short messages

Checked Open Submissions Checked Indexed Unchecked Peer Reviewed
 

Peer Review Process

A double-blind peer review method is mandatory for processing of all scientific manuscripts submitted to the editorial stuff of “Clinical and experimental thyroidology”. This implies that neither the reviewer is aware of the authorship of the manuscript, nor the author maintains any contact with the reviewer.

  1. Members of the editorial board and leading Russian and international experts in corresponding areas of life sciences, invited as independent readers, perform peer reviews. Editor-in-chief, deputy editor-in-chief or science editor choose readers for peer review. We aim to limit the review process to 2-4 weeks, though in some cases the schedule may be adjusted at the reviewer’s request.
  2. Reviewer has an option to abnegate the assessment should any conflict of interests arise that may affect perception or interpretation of the manuscript. Upon the scrutiny, the reviewer is expected to present the editorial board with one of the following recommendations: to accept the paper in its present state; to invited the author to revise their manuscript to address specific concerns before final decision is reached; that final decision be reached following further reviewing by another specialist; to reject the manuscript outright.
  3. If the reviewer has recommended any refinements, the editorial staff would suggest the author either to implement the corrections, or to dispute them reasonably. Authors are kindly required to limit their revision to 2 months and resubmit the adapted manuscript within this period for final evaluation.
  4. We politely request that the editor be notified verbally or in writing should the author decide to refuse from publishing the manuscript. In case the author fails to do so within 3 months since receiving a copy of the initial review, the editorial board takes the manuscript off the register and notifies the author accordingly.
  5. If author and reviewers meet insoluble contradictions regarding revision of the manuscript, the editor-in-chief resolves the conflict by his own authority.
  6. The editorial board reaches final decision to reject a manuscript on the hearing according to reviewers’ recommendations, and duly notifies the authors of their decision via e-mail. The board does not accept previously rejected manuscripts for re-evaluation.
  7. Upon the decision to accept the manuscript for publishing, the editorial staff notifies the authors of the scheduled date of publication.
  8. Kindly note that positive review does not guarantee the acceptance, as final decision in all cases lies with the editorial board. By his authority, editor-in-chief rules final solution of every conflict.
  9. Original reviews of submitted manuscripts remain deposited permanently (not less than 5 years).
  10. Manuscript reviews are not published. Reviews can be sent to the Ministry of Education and Sciense of Russian Federation in case of query.

 

Open Access Policy

This journal provides immediate open access to its content on the principle that making research freely available to the public supports a greater global exchange of knowledge.

 

Indexing

Articles in "Clinical and experimental thyroidology" journal are indexed by several systems:

 

Publication Ethics

The Ethic policy of "Clinical and Experimental Thyroidology" journal is based on recomendations from international commettees:

  

 

Reporting standarts

Authors of reports of original research should present an accurate account of the work performed as well as an objective discussion of its significance. Underlying data should be represented accurately in the paper. A paper should contain sufficient detail and references to permit others to replicate the work. Fraudulent or knowingly inaccurate statements constitute unethical behavior and are unacceptable.

Review and professional publication articles should also be accurate and objective, and editorial opinion works should be clearly identified as such.

Data Access and Retention

Authors may be asked to provide the raw data in connection with a paper for editorial review, and should be prepared to provide public access to such data (consistent with the ALPSP-STM Statement on Data and Databases), if practicable, and should in any event be prepared to retain such data for a reasonable time after publication.

Originality and Plagiarism

Plagiarism takes many forms, from passing off another paper as the author(s) own paper, to copying or paraphrasing substantial parts of another(s) paper (without attribution), to claiming results from research conducted by others. Plagiarism in all its forms constitutes unethical publishing behavior and is unacceptable.

Only original works are acceptable for publication in "Clinical and experimental thyroidology" journal. The journal does not allow any forms of plagiarism.

If the authors have used the work and/or words of others, that this has been appropriately cited or quoted.

The journal is using "ANTIPLAGIAT" (free edition) software for plagiarism detection in all Russian-language manuscripts. The Google Scholar is used for English-language manuscripts. Papers will be rejected from any stage of the publication process(even if the article were published already) if plagiarism will be fined.

Papers will be rejected from any stage of the publication process (even if the article were publishedalready) if plagiarism will be fined.

Multiple, Redundant or Concurrent Publication

An author should not in general publish manuscripts describing essentially the same research in more than one journal or primary publication. Submitting the same manuscript to more than one journal concurrently constitutes unethical publishing behaviour and is unacceptable.

In general, an author should not submit for consideration in another journal a previously published paper. Publication of some kinds of articles (eg, clinical guidelines, translations) in more than one journal is sometimes justifiable, provided certain conditions are met. The authors and editors of the journals concerned must agree to the secondary publication, which must reflect the same data and interpretation of the primary document. The primary reference must be cited in the secondary publication. Further detail on acceptable forms of secondary publication can be found at http://www.icmje.org/

Acknowledgement of Sources

Proper acknowledgment of the work of others must always be given. Authors should cite publications that have been influential in determining the nature of the reported work. Information obtained privately, as in conversation, correspondence, or discussion with third parties, must not be used or reported without explicit, written permission from the source. Information obtained in the course of confidential services, such as refereeing manuscripts or grant applications, must not be used without the explicit written permission of the author of the work involved in these services.

Authorship of the Paper

Authorship should be limited to those who have made a significant contribution to the conception, design, execution, or interpretation of the reported study. All those who have made significant contributions should be listed as co-authors. Where there are others who have participated in certain substantive aspects of the research project, they should be acknowledged or listed as contributors.

The corresponding author should ensure that all appropriate co-authors and no inappropriate co-authors are included on the paper, and that all co-authors have seen and approved the final version of the paper and have agreed to its submission for publication.

Hazards and Human or Animal Subjects

If the work involves chemicals, procedures or equipment that have any unusual hazards inherent in their use, the author must clearly identify these in the manuscript. If the work involves the use of animal or human subjects, the author should ensure that the manuscript contains a statement that all procedures were performed in compliance with relevant laws and institutional guidelines and that the appropriate institutional committee(s) have approved them. Authors should include a statement in the manuscript that informed consent was obtained for experimentation with human subjects. The privacy rights of human subjects must always be observed.

Statement of Human and Animal Rights

When reporting experiments on human subjects, authors should indicate whether the procedures followed were in accordance with the ethical standards of the responsible committee on human experimentation (institutional and national) and with the Helsinki Declaration of 1975, as revised in 2000 and 2008. If doubt exists whether the research was conducted in accordance with the Helsinki Declaration, the authors must explain the rationale for their approach, and demonstrate that the institutional review body explicitly approved the doubtful aspects of the study.

When reporting experiments on animals, authors should be asked to indicate whether the institutional and national guide for the care and use of laboratory animals was followed.

Disclosure and Conflicts of Interest

All authors should disclose in their manuscript any financial or other substantive conflict of interest that might be construed to influence the results or interpretation of their manuscript. All sources of financial support for the project should be disclosed.

Examples of potential conflicts of interest which should be disclosed include employment, consultancies, stock ownership, honoraria, paid expert testimony, patent applications/registrations, and grants or other funding. Potential conflicts of interest should be disclosed at the earliest stage possible.

Fundamental errors in published works

When an author discovers a significant error or inaccuracy in his/her own published work, it is the authors obligation to promptly notify the journal editor or publisher and cooperate with the editor to retract or correct the paper. If the editor or the publisher learn from a third party that a published work contains a significant error, it is the obligation of the author to promptly retract or correct the paper or provide evidence to the editor of the correctness of the original paper.

----

The page is based on original materials from the Elsevier: http://cdn.elsevier.com/promis_misc/ethicalguidelinesforauthors.pdf

 

Publication Fee

Publication in "Clinical and Experimental Thyroidology" journal is free for all authors.

The "Clinical and Experimental Thyroidology" journal charge no publication fees for authors - including those of peer-review management, manuscripr processing, journal production, Open-Access, online hosting and archiving.